Microarray analysis identified the downregulation of DUSP4, a known inhibitor of ERK, in serous ovarian carcinomas, in contrast to ovarian serous borderline tumors, suggesting a potential tool in ovarian cancer diagnosis and patient management [29,30]. Here, MAPK1 is linked to ovarian serous carcinoma.